Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
מצבים רפואיים
Recurrent Acute Lymphoblastic Leukemia · Recurrent B Acute Lymphoblastic Leukemia · Recurrent B-Cell Prolymphocytic Leukemia · Recurrent Chronic Lymphocytic Leukemia · Recurrent High Grade B-Cell Lymphoma · Recurrent Indolent Non-Hodgkin Lymphoma · Recurrent Non-Hodgkin Lymphoma · Recurrent Transformed Chronic Lymphocytic Leukemia · Refractory Acute Lymphoblastic Leukemia · Refractory B Acute Lymphoblastic Leukemia · Refractory B-Cell Prolymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia · Refractory High Grade B-Cell Lymphoma · Refractory Indolent Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Refractory Transformed Chronic Lymphocytic Leukemia · Refactory Childhood Acute Lymphoblastic Leukemia · Refractory Childhood Non-Hodgkin Lymphoma
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Kennedy Thompson) · Kennedy.thompson@nationwidechildrens.org · 614-722-5043Contact: Principal Investigator (Margaret Lamb, MD)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Sumithira Vasu, MD)
מובילי המחקר
Sumithira Vasu, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center